Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona
Avacta Group PLC (AIM:AVCT) Avacta and Tempus Enter Strategic Collaboration
Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology
Avacta: The British Biotech Disrupting Cancer Treatment
Who is Avacta?
Avacta Group PLC (AIM:AVCT) Avacta Expands its Pipeline
Avacta Expands its Pipeline with Two Novel Assets Developed Using its pre|CISION® Platform
Avacta Group PLC (AIM:AVCT) Avacta appoints Chief Scientific Officer
Avacta Group strengthens executive team with appointment of Michelle Morrow, PhD as Chief Scientific Officer.
Avacta Group PLC – Avacta Unveils Pipeline Expansion at EORTC 2024
Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium
Avacta Group PLC – Avacta to present clinical data at ESMO Congress
Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress
Avacta Group PLC (AIM:AVCT) Update on Convertible Bond Payment
Avacta Group plc (AIM: AVCT), a clinical stage life sciences company developing innovative, targeted cancer treatments and powerful diagnostics today announces that it has elected to settle in cash the
Avacta Group plc (AIM: AVCT) AGM Business Update
AGM Business Update Second Cohort in the AVA6000 Phase 1 Arm 2 Completed, Patient Dosing is Ongoing in Cohort Three Avacta Announces the Assembly of a Scientific Advisory Board to
Avacta Group PLC (AIM:AVCT) Successful Completion of First Cohort
Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta’s AVA6000 Phase 1 trial Initiation of FAPI-PET Sub-study in the
Avacta Group PLC (AIM:AVCT) AVA6000 Abstract Release by AACR and Full Presentation Update
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that the abstract of the poster to be presented at the
Avacta Group PLC (AIM:AVCT) Update on AVA6000 Phase 1a Clinical Trial Progress
Three patients now dosed in the US in two-weekly dose escalation study Avacta receives approval to enrol patients in the UK in the ongoing two-weekly dose escalation study